First City Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

First City Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-25,670	Closed	-$853K	–	144
2017 Q2	$853K	Sell	25,670 -1,000	-4%	-$31K	0.62%	58
2017 Q1	$856K	Buy	26,670 +100	+0.4%	+$3.41K	0.63%	55
2016 Q4	$963K	Buy	26,570 +14,635	+123%	+$584K	0.72%	50
2016 Q3	$549K	Buy	+11,935	New	+$623K	0.42%	69
2016 Q2	–	Sell	-2,965	Closed	-$159K	–	478
2016 Q1	$159K	Hold	2,965	–	–	0.11%	149
2015 Q4	$195K	Buy	+2,965	New	+$183K	0.13%	130
2015 Q2	–	Sell	-730	Closed	-$45.5K	–	633
2015 Q1	$45.5K	Buy	730 +325	+80%	+$18.9K	0.03%	285
2014 Q4	$23.3K	Hold	405	–	–	0.02%	359
2014 Q3	$21.8K	Sell	405 -90	-18%	-$4.77K	0.02%	352
2014 Q2	$25.9K	Hold	495	–	–	0.02%	348
2014 Q1	$26.2K	Buy	+495	New	+$22.9K	0.02%	344

Other funds holding TEVA

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

First City Capital Management's TEVA Position: Q3 2017 in Review

First City Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 25,670 shares — an estimated $853K sold.

First City Capital Management first reported a position in TEVA in Q1 2014 and held it in 11 quarters. The position peaked at $963K in Q4 2016. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

First City Capital Management reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
First City Capital Management sold 25,670 Teva Pharmaceuticals shares in Q3 2017, an estimated $853K.
First City Capital Management first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 11 quarters.
First City Capital Management's Teva Pharmaceuticals position peaked at $963K in Q4 2016.
535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on First City Capital Management's 13F filing for Q3 2017, filed 31 Oct 2017.